Meropenem Qilu (Meropenem)

Meropenem exerts its effect by binding irreversibly to penicillin‑binding proteins on the bacterial cell wall, blocking the final step of peptidoglycan cross‑linking. This inhibition weakens the cell wall, leading to osmotic rupture and bacterial cell death, providing rapid bactericidal activity against a wide range of pathogens.

The dose of Meropenem Qilu is determined by the prescribing clinician based on the type and severity of infection, the patient’s renal function, age, weight, and any concomitant medications. No fixed regimen can be provided here; the prescriber will tailor the dosage to each individual case.

Meropenem is classified as pregnancy category B, indicating that animal studies have not shown risk to the fetus and there are no adequate human studies. It should be used in pregnancy only if the potential benefit justifies any potential risk. Limited data are available for breastfeeding, so a risk‑benefit assessment is required.

To order Meropenem Qilu, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the enquiry, the sales team will request trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Meropenem shares the broad‑spectrum, β‑lactam activity typical of carbapenems but has a slightly lower affinity for certain resistant enzymes compared with imipenem or ertapenem. It is often chosen for infections where a high degree of bacterial coverage, including Pseudomonas and anaerobes, is required, and when the patient’s renal function allows standard dosing.

Meropenem Qilu should be stored at ambient temperature, below 25 °C, in its original packaging. The container should be kept away from moisture, direct sunlight and extreme temperatures. Once reconstituted, follow the manufacturer’s guidance for stability and discard any unused portion after the recommended time.

Meropenem Qilu is supplied as an injectable solution for intravesical administration. The preparation is diluted according to the prescribing information and infused slowly into the bladder via a catheter. Administration must be performed by qualified healthcare personnel under aseptic conditions.

The most serious adverse events linked to Meropenem include seizures (especially in patients with renal impairment or pre‑existing CNS disorders), Clostridioides difficile‑associated colitis, and severe hypersensitivity reactions such as anaphylaxis. Prompt recognition and medical intervention are essential if any of these events occur.

Meropenem Qilu is contraindicated in patients with a known hypersensitivity to meropenem, other carbapenems, or any β‑lactam antibiotics. It should also be avoided in individuals with a history of severe allergic reactions to related drugs. Caution is advised for patients with severe renal impairment, as dose adjustments are required.